Immunex Corporation

Sterling Winthrop Inc.

Other

Sanofi

Sanofi-synthelabo

Raymond G Goodwin

Craig A Smith

M Patricia Beckmann

Richard Jeffrey Armitage

Stephen D Lupton

Diane Y Mochizuki

Anthony E Namen

Steven R Wiley

Hans-Juergen Gruss

Mark R Alderson

Linda S Park

William Christian Fanslow, Iii

Peter Robert Baum

Richard B Gayle, Iii

Judith G Giri

Mariapia A Degli-Esposti Rankin

Wanwan S Din

The invention discloses a novel interaction between a TNF receptor (TACI) and its interacting ligand (TACI-L). Also disclosed are methods of screening candidate molecules to determine potential antagonists and agonists of the TACI/TACI-L interaction. The use of the antagonists and agonists as therapeutics to treat autoimmune diseases, inflammation, and to inhibit graft vs. host rejections is further disclosed.

Methods of use of the TACI/TACI-L interaction

A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.

DNA encoding a soluble fragment of TRAIL polypeptide

Use of TRAIL polypeptides to induce apoptosis

Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.

Glycoproteins which bind to TNF

Isolated apoptosis inducing receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.

Receptor that causes cell death and recombinant production thereof

There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.

CD30 ligand

Novel 4-1BB ligand (4-1BB-L) polypeptides and a human cell surface receptor designated 4-1BB that binds 4-1BB-L are provided. Isolated 4-1BB-L-encoding and human 4-1BB-encoding DNA sequences, recombinant expression vectors comprising the isolated DNA sequences, and host cells transformed with the recombinant expression vectors are disclosed, along with methods for producing the novel polypeptides by cultivating such transformed host cells. Soluble forms of the 4-1BB-L or 4-1BB polypeptides are derived from the extracellular domains thereof.

4-1BB polypeptides and DNA encoding 4-1BB polypeptides

Antibodies to human 4-1BB

Tumor necrosis factor receptor proteins, DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.

Antibodies which specifically bind to TNF-R

A poxvirus protein designated A41L binds to leukocyte common-antigen-related protein (LAR). A41L is a secreted protein that can be purified from the culture supernatant of cells infected with certain poxviruses, or produced using recombinant DNA techniques. A41L polypeptides and LAR polypeptides, and nucleic acids encoding them, are provided herein. Also provided are methods of using such polypeptides and nucleic acids.

Viral proteins capable of binding LAR

There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplasdic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.

Method for suppressing inflammatory responses by administering TNFR

Antibodies directed against trail

Cytokine designated 4-1BB ligand antibodies and human receptor that binds thereto

Cytokine that induces apoptosis

Growing community of inventors

Seattle, WA, United States of America

Raymond G Goodwin